#United States #Class Action #New Orleans #Securities Laws #Capricor Therapeutics

Capricor Therapeutics Faces Class Action Lawsuit

Capricor Therapeutics, Inc. is currently under scrutiny after an alarming decline in its stock price, prompting investors to take legal action. According to the latest reports, the U.S. Food and Drug Administration (FDA) raised serious concerns regarding the company's leading product candidate, Deramiocel, which has led to a significant drop in investor confidence.

The Timeline of Events

On July 27, 2026, the FDA published briefing documents that indicated Capricor had allegedly altered the statistical analysis plan prior to submitting the Biologics License Application (BLA) for Deramiocel. The briefing pointed out that the statistical plan—the final version of which had not been agreed with the FDA—was modified just a day before the data was made public. Furthermore, the FDA criticized these modifications, stating that they undermined the accuracy of the study's findings.

Long-standing investors of Capricor are reminded that the deadline to file lead plaintiff applications in this emerging securities class action is September 28, 2026. This alert is specifically aimed at those who purchased Capricor's shares between December 17, 2025 and July 26, 2026, as their investments may have suffered significant losses.

Allegations Against Capricor Therapeutics

The key allegations revolve around the idea that the company knowingly failed to disclose important information relating to its product candidates during the class period, which could constitute a violation of federal securities laws. Following the negative news from the FDA, Capricor’s stock plummeted by approximately 64%, falling from a previous close of $12.70 to $7.00 per share, which has raised concerns among investors.

As a result, a class action lawsuit has been initiated, with the case named Nkamga v. Capricor Therapeutics, Inc., currently pending in the United States District Court for the Southern District of California. Capricor’s executives are accused of misleading shareholders regarding the viability and safety of their product, which compounded the investors' losses when news emerged about the unfavorable FDA reports.

Seeking Recovery Through ClaimsFiler

For investors feeling the impact of these events, ClaimsFiler serves as an essential resource. It allows individuals to understand their legal options and file claims if they qualify. According to ClaimsFiler, those with losses exceeding $100,000 are particularly encouraged to consider joining the class action to potentially recoup their losses. The ClaimsFiler website provides valuable information and updates about ongoing cases and offers a free registration service for affected investors.

To see if you are eligible or to seek legal advice, you can visit ClaimsFiler's dedicated webpage or reach out to them via their toll-free number, which is also available for inquiries related to this matter.

Conclusion

The timeline leading to the class action against Capricor Therapeutics underscores the volatile nature of biotech stocks and the critical importance of transparency from corporations. Investors are urged to stay informed and consider the implications of this case not only for their current investments but for future corporate governance practices across the biotech industry. With a firm deadline approaching, the focus is now on how this legal proceeding will unfold and what it could mean for investors who placed their trust in Capricor's future.